| Literature DB >> 31337589 |
A Alcántara Montero1, P J Ibor Vidal2, A Alonso Verdugo3, E Trillo Calvo4.
Abstract
We provide an updated review of the pharmacological treatment of neuropathic pain, with emphasis on the latest evidence-based recommendations. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin-noradrenaline reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second-line treatments include 5% lidocaine medicated plasters and capsaicin 8% patches, only for peripheral neuropathic pain and tramadol; whereas potent opioids and botulinum toxin A (for peripheral neuropathic pain) are considered third-line treatments. Future perspectives include the development of new drugs and a more personalised therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain.Entities:
Keywords: Dolor neuropático; Emerging therapies; Farmacoterapia; Medicina personalizada; Neuropathic pain; Personalised medicine; Pharmacotherapy; Recomendaciones; Recommendations; Terapias emergentes
Mesh:
Year: 2019 PMID: 31337589 DOI: 10.1016/j.semerg.2019.05.008
Source DB: PubMed Journal: Semergen ISSN: 1138-3593